EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advances in Nanomaterials for Immunotherapeutic Improvement of Cancer Chemotherapy

Jie Liu iD, Bei Li, Li Li, Xin Ming, Zhi Ping Xu iD

Small · 2024

DOI: 10.1002/smll.202403024 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Small, 2024. Verfasst von Jie Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Australian Institute for Bioengineering and Nanotechnology, the University of Queensland, St Lucia, QLD, 4072, Australia. Hauptthemen laut MEDLINE: Immunotherapy, Neoplasms, Nanostructures. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 291 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immuno‐stimulative effect of chemotherapy (ISECT) is recognized as a potential alternative to conventional immunotherapies, however, the clinical application is constrained by its inefficiency. Metronomic chemotherapy, though designed to overcome these limitations, offers inconsistent results, with effectiveness varying based on cancer types, stages, and patient‐specific factors. In parallel, a wealth of preclinical nanomaterials holds considerable promise for ISECT improvement by modulating the cancer‐immunity cycle. In the area of biomedical nanomaterials, current literature reviews mainly concentrate on a specific category of nanomaterials and nanotechnological perspectives, while two essential issues are still lacking, i.e., a comprehensive analysis addressing the causes for ISECT inefficiency and a thorough summary elaborating the nanomaterials for ISECT improvement. This review thus aims to fill these gaps and catalyze further development in this field. For the first time, this review comprehensively discusses the causes of ISECT inefficiency. It then meticulously categorizes six types of nanomaterials for improving ISECT. Subsequently, practical strategies are further proposed for addressing inefficient ISECT, along with a detailed discussion on exemplary nanomedicines. Finally, this review provides insights into the challenges and perspectives for improving chemo‐immunotherapy by innovations in nanomaterials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyNeoplasmsNanostructuresHumansAnimalsNanomedicine

Stichwörter der Autor:innen

chemotherapyimmunogenicityimmunotherapynanomaterial

Autor:innen und Institutionen

  • Australian Institute for Bioengineering and Nanotechnology, the University of Queensland, St Lucia, QLD, 4072, Australia.
  • School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, 000000, China.
  • GoodMedX Tech Limited Company, Hong Kong SAR, 000000, China.
  • Cancer Centre and Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macau SAR, 999078, China.
  • Departments of Cancer Biology and Biomedical Engineering, Wake Forest University School of Medicine, Winston-Salem, North Carolina, 27157, USA.
  • Institute of Biomedical Health Technology and Engineering, and Institute of Systems and Physical Biology, Shenzhen Bay Laboratory, Shenzhen, Guangdong Province, 518107, China.

ORCID-Profile: Jie Liu, Zhi Ping Xu

Zitieren

APA

Liu, J., Li, B., Li, L., Ming, X., & Xu, Z. P. (2024). Advances in Nanomaterials for Immunotherapeutic Improvement of Cancer Chemotherapy. Small. https://doi.org/10.1002/smll.202403024

Vancouver

Liu J, Li B, Li L, Ming X, Xu ZP. Advances in Nanomaterials for Immunotherapeutic Improvement of Cancer Chemotherapy. Small. 2024. doi:10.1002/smll.202403024

BibTeX
@article{Liu2024,
  author = {Liu, Jie and Li, Bei and Li, Li and Ming, Xin and Xu, Zhi Ping},
  title = {Advances in Nanomaterials for Immunotherapeutic Improvement of Cancer Chemotherapy},
  journal = {Small},
  year = {2024},
  doi = {10.1002/smll.202403024}
}
Kostenlos starten →